Duration of detection of anti-BmR1 IgG4 antibodies after mass-drug administration (MDA) in Sarawak, Malaysia.
Identifieur interne : 002146 ( PubMed/Corpus ); précédent : 002145; suivant : 002147Duration of detection of anti-BmR1 IgG4 antibodies after mass-drug administration (MDA) in Sarawak, Malaysia.
Auteurs : R. Noordin ; J. Muhi ; Z. Md Idris ; N. Arifin ; A. KiyuSource :
- Tropical biomedicine [ 0127-5720 ] ; 2012.
English descriptors
- KwdEn :
- Adolescent, Adult, Aged, Aged, 80 and over, Animals, Antibodies, Helminth (blood), Antigens, Helminth, Brugia (immunology), Child, Child, Preschool, Drug Therapy (methods), Elephantiasis, Filarial (drug therapy), Elephantiasis, Filarial (epidemiology), Elephantiasis, Filarial (immunology), Filaricides (administration & dosage), Humans, Immunoglobulin G (blood), Malaysia (epidemiology), Male, Middle Aged, Recombinant Proteins, Seroepidemiologic Studies, Time Factors, Young Adult.
- MESH :
- chemical , administration & dosage : Filaricides.
- chemical , blood : Antibodies, Helminth, Immunoglobulin G.
- geographic , epidemiology : Malaysia.
- drug therapy : Elephantiasis, Filarial.
- epidemiology : Elephantiasis, Filarial.
- immunology : Brugia, Elephantiasis, Filarial.
- methods : Drug Therapy.
- Adolescent, Adult, Aged, Aged, 80 and over, Animals, Antigens, Helminth, Child, Child, Preschool, Humans, Male, Middle Aged, Recombinant Proteins, Seroepidemiologic Studies, Time Factors, Young Adult.
Abstract
The detection rates of brugian filariasis in three regions of Sarawak namely Central, North and South after three courses of mass drug administration (MDA) from year 2004 to 2006 was investigated. A recombinant BmR1 antigen-based IgG4 detection test, named Brugia Rapid and night blood smear for microfilaria (mf) detection were used. All three regions recorded a sharp fall in mf positive rates after a year post-MDA. Meanwhile Brugia Rapid positive rates declined more gradually to 3.8% and 5.6% of the pre-MDA levels in the Central and North regions, respectively. This study showed that in filariasis endemic areas in Sarawak, anti-filarial IgG4 antibodies to BmR1, as detected by the Brugia Rapid test, were positive for one to two years after mf disappearance.
PubMed: 22543621
Links to Exploration step
pubmed:22543621Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Duration of detection of anti-BmR1 IgG4 antibodies after mass-drug administration (MDA) in Sarawak, Malaysia.</title><author><name sortKey="Noordin, R" sort="Noordin, R" uniqKey="Noordin R" first="R" last="Noordin">R. Noordin</name><affiliation><nlm:affiliation>Institute for Research in Molecular Medicine (INFORMM), Universiti Sains Malaysia, Penang, Malaysia. rahmah8485@gmail.com</nlm:affiliation></affiliation></author><author><name sortKey="Muhi, J" sort="Muhi, J" uniqKey="Muhi J" first="J" last="Muhi">J. Muhi</name></author><author><name sortKey="Md Idris, Z" sort="Md Idris, Z" uniqKey="Md Idris Z" first="Z" last="Md Idris">Z. Md Idris</name></author><author><name sortKey="Arifin, N" sort="Arifin, N" uniqKey="Arifin N" first="N" last="Arifin">N. Arifin</name></author><author><name sortKey="Kiyu, A" sort="Kiyu, A" uniqKey="Kiyu A" first="A" last="Kiyu">A. Kiyu</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2012">2012</date><idno type="RBID">pubmed:22543621</idno><idno type="pmid">22543621</idno><idno type="wicri:Area/PubMed/Corpus">002146</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002146</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Duration of detection of anti-BmR1 IgG4 antibodies after mass-drug administration (MDA) in Sarawak, Malaysia.</title><author><name sortKey="Noordin, R" sort="Noordin, R" uniqKey="Noordin R" first="R" last="Noordin">R. Noordin</name><affiliation><nlm:affiliation>Institute for Research in Molecular Medicine (INFORMM), Universiti Sains Malaysia, Penang, Malaysia. rahmah8485@gmail.com</nlm:affiliation></affiliation></author><author><name sortKey="Muhi, J" sort="Muhi, J" uniqKey="Muhi J" first="J" last="Muhi">J. Muhi</name></author><author><name sortKey="Md Idris, Z" sort="Md Idris, Z" uniqKey="Md Idris Z" first="Z" last="Md Idris">Z. Md Idris</name></author><author><name sortKey="Arifin, N" sort="Arifin, N" uniqKey="Arifin N" first="N" last="Arifin">N. Arifin</name></author><author><name sortKey="Kiyu, A" sort="Kiyu, A" uniqKey="Kiyu A" first="A" last="Kiyu">A. Kiyu</name></author></analytic><series><title level="j">Tropical biomedicine</title><idno type="ISSN">0127-5720</idno><imprint><date when="2012" type="published">2012</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Animals</term><term>Antibodies, Helminth (blood)</term><term>Antigens, Helminth</term><term>Brugia (immunology)</term><term>Child</term><term>Child, Preschool</term><term>Drug Therapy (methods)</term><term>Elephantiasis, Filarial (drug therapy)</term><term>Elephantiasis, Filarial (epidemiology)</term><term>Elephantiasis, Filarial (immunology)</term><term>Filaricides (administration & dosage)</term><term>Humans</term><term>Immunoglobulin G (blood)</term><term>Malaysia (epidemiology)</term><term>Male</term><term>Middle Aged</term><term>Recombinant Proteins</term><term>Seroepidemiologic Studies</term><term>Time Factors</term><term>Young Adult</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Filaricides</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Antibodies, Helminth</term><term>Immunoglobulin G</term></keywords><keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en"><term>Malaysia</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Elephantiasis, Filarial</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Elephantiasis, Filarial</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Brugia</term><term>Elephantiasis, Filarial</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Drug Therapy</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Animals</term><term>Antigens, Helminth</term><term>Child</term><term>Child, Preschool</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Recombinant Proteins</term><term>Seroepidemiologic Studies</term><term>Time Factors</term><term>Young Adult</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The detection rates of brugian filariasis in three regions of Sarawak namely Central, North and South after three courses of mass drug administration (MDA) from year 2004 to 2006 was investigated. A recombinant BmR1 antigen-based IgG4 detection test, named Brugia Rapid and night blood smear for microfilaria (mf) detection were used. All three regions recorded a sharp fall in mf positive rates after a year post-MDA. Meanwhile Brugia Rapid positive rates declined more gradually to 3.8% and 5.6% of the pre-MDA levels in the Central and North regions, respectively. This study showed that in filariasis endemic areas in Sarawak, anti-filarial IgG4 antibodies to BmR1, as detected by the Brugia Rapid test, were positive for one to two years after mf disappearance.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22543621</PMID><DateCreated><Year>2012</Year><Month>04</Month><Day>30</Day></DateCreated><DateCompleted><Year>2012</Year><Month>08</Month><Day>15</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0127-5720</ISSN><JournalIssue CitedMedium="Internet"><Volume>29</Volume><Issue>1</Issue><PubDate><Year>2012</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Tropical biomedicine</Title><ISOAbbreviation>Trop Biomed</ISOAbbreviation></Journal><ArticleTitle>Duration of detection of anti-BmR1 IgG4 antibodies after mass-drug administration (MDA) in Sarawak, Malaysia.</ArticleTitle><Pagination><MedlinePgn>191-6</MedlinePgn></Pagination><Abstract><AbstractText>The detection rates of brugian filariasis in three regions of Sarawak namely Central, North and South after three courses of mass drug administration (MDA) from year 2004 to 2006 was investigated. A recombinant BmR1 antigen-based IgG4 detection test, named Brugia Rapid and night blood smear for microfilaria (mf) detection were used. All three regions recorded a sharp fall in mf positive rates after a year post-MDA. Meanwhile Brugia Rapid positive rates declined more gradually to 3.8% and 5.6% of the pre-MDA levels in the Central and North regions, respectively. This study showed that in filariasis endemic areas in Sarawak, anti-filarial IgG4 antibodies to BmR1, as detected by the Brugia Rapid test, were positive for one to two years after mf disappearance.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Noordin</LastName><ForeName>R</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Institute for Research in Molecular Medicine (INFORMM), Universiti Sains Malaysia, Penang, Malaysia. rahmah8485@gmail.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Muhi</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Md Idris</LastName><ForeName>Z</ForeName><Initials>Z</Initials></Author><Author ValidYN="Y"><LastName>Arifin</LastName><ForeName>N</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Kiyu</LastName><ForeName>A</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Malaysia</Country><MedlineTA>Trop Biomed</MedlineTA><NlmUniqueID>8507086</NlmUniqueID><ISSNLinking>0127-5720</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000909">Antibodies, Helminth</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000947">Antigens, Helminth</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005369">Filaricides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007074">Immunoglobulin G</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000909" MajorTopicYN="N">Antibodies, Helminth</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000947" MajorTopicYN="N">Antigens, Helminth</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002009" MajorTopicYN="N">Brugia</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004358" MajorTopicYN="N">Drug Therapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004605" MajorTopicYN="N">Elephantiasis, Filarial</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005369" MajorTopicYN="N">Filaricides</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007074" MajorTopicYN="N">Immunoglobulin G</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008296" MajorTopicYN="N" Type="Geographic">Malaysia</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011994" MajorTopicYN="N">Recombinant Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016036" MajorTopicYN="N">Seroepidemiologic Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>5</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>5</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>8</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22543621</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002146 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 002146 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:22543621
|texte= Duration of detection of anti-BmR1 IgG4 antibodies after mass-drug administration (MDA) in Sarawak, Malaysia.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:22543621" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a LymphedemaV1
| This area was generated with Dilib version V0.6.31. |  |